Indivior to Report Second Quarter 2026 Financial Results and Host Webcast
Globe Newswire (Thu, 23-Jul 10:00 AM ET)
Globe Newswire (Wed, 20-May 9:00 AM ET)
Indivior to Participate in Upcoming Investor Conferences
Globe Newswire (Thu, 14-May 7:00 AM ET)
Indivior Announces $175 Million Accelerated Share Repurchase
Globe Newswire (Mon, 4-May 7:00 AM ET)
Indivior Ups Full-Year Guidance After Record Q1 Growth in SUBLOCADE and EBITDA
Market Chameleon (Thu, 30-Apr 4:23 AM ET)
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
Globe Newswire (Thu, 30-Apr 7:00 AM ET)
INDV to Join S&P SmallCap 600: Index Inclusion Highlights Growing Market Presence
Market Chameleon (Mon, 8-Dec 6:55 AM ET)
Indivior to Join S&P SmallCap 600—What Could This Index Addition Mean for Investors?
Market Chameleon (Mon, 8-Dec 4:11 AM ET)
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
Indivior Pharmaceuticals trades on the NASDAQ stock market under the symbol INDV.
As of July 30, 2026, INDV stock price climbed to $40.28 with 220,448 million shares trading.
INDV has a beta of -0.10, meaning it tends to be less sensitive to market movements. INDV has a correlation of 0.00 to the broad based SPY ETF.
INDV has a market cap of $4.76 billion. This is considered a Mid Cap stock.
Last quarter Indivior Pharmaceuticals reported $317 million in Revenue and $.96 earnings per share. This beat revenue expectation by $45 million and exceeded earnings estimates by $.30.
In the last 3 years, INDV traded as high as $42.81 and as low as $7.33.
The top ETF exchange traded funds that INDV belongs to (by Net Assets): IJR, VTI, IWM, VB, XSMO.
INDV has outperformed the market in the last year with a price return of +133.1% while the SPY ETF gained +17.2%. INDV has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +18.0% and -1.6%, respectively, while the SPY returned +3.8% and -2.4%, respectively.
INDV support price is $39.22 and resistance is $40.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INDV shares will trade within this expected range on the day.